What is Synuclein?
Synuclein is a small, soluble protein primarily expressed in neural tissue, particularly concentrated in the presynaptic terminals of neurons. While its exact physiological function remains under investigation, it is widely recognized for its role in regulating synaptic vesicle trafficking and neurotransmitter release. The pathological hallmark of a group of neurodegenerative disorders known as synucleinopathies is the abnormal accumulation and aggregation of misfolded synuclein. This aggregation forms insoluble fibrils that cluster into Lewy bodies or glial cytoplasmic inclusions (GCIs), depending on the specific disease.
Multiple System Atrophy and Parkinsonism
Multiple system atrophy (MSA) is a fatal, adult-onset synucleinopathy characterized by a devastating combination of autonomic failure, cerebellar ataxia, and parkinsonism. Unlike Parkinson's disease, where synuclein aggregates primarily in neurons, MSA is defined by the accumulation of GCIs within oligodendrocytes. This distinctive pathology drives widespread neurodegeneration. Parkinsonism in MSA typically presents as bradykinesia, rigidity, and postural instability, but it often responds poorly to levodopa therapy. The overlap in motor symptoms can make early diagnosis challenging, yet the presence of additional features such as cerebellar dysfunction and severe autonomic failure often differentiates MSA from idiopathic Parkinson's disease.
Imbalance and Autonomic Dysfunction
One of the most disabling features of multiple system atrophy is severe imbalance. This arises from a combination of cerebellar degeneration (leading to ataxia) and loss of proprioceptive integration in the basal ganglia. Patients frequently experience sudden falls and significant gait instability. Alongside motor imbalance, autonomic failure is a core component of MSA. A key manifestation is orthostatic hypotension—a dangerous drop in blood pressure upon standing that can cause lightheadedness, syncope, and falls. This symptom results from degeneration of preganglionic autonomic neurons in the brainstem and spinal cord, which are heavily affected by synuclein pathology.
Orthostatic Hypotension and Slow Eye Movements
Orthostatic hypotension is often one of the earliest presenting symptoms of MSA. It is typically more severe than in other synucleinopathies and may require aggressive management with fludrocortisone, midodrine, and non-pharmacological measures like compression stockings and dietary salt. In addition to autonomic and motor symptoms, patients with MSA may develop oculomotor abnormalities. Slow eye movements, particularly vertical saccades, are frequently observed. This impairment is linked to degeneration of the brainstem saccade-generating centers, such as the paramedian pontine reticular formation and the rostral interstitial nucleus of the medial longitudinal fasciculus. The combination of orthostatic hypotension with slow eye movements and parkinsonism strongly suggests the diagnosis of MSA over other conditions.
The Role of Tau and Shared Pathologies
While synuclein is the primary pathological protein in MSA, research increasingly points to interactions between synuclein and other proteins, notably tau. Tau is a microtubule-associated protein that forms neurofibrillary tangles in Alzheimer's disease and various tauopathies. In MSA, tau pathology can co-occur, particularly in neurons, and may exacerbate neurodegeneration. The interplay between aggregated synuclein and hyperphosphorylated tau suggests a potential synergistic mechanism driving disease progression. Understanding these cross-seeding interactions is a critical frontier for developing therapies that target both proteins.
Conclusion and Future Directions
The journey from the discovery of synuclein to its central role in multiple system atrophy has transformed our understanding of neurodegenerative disease. The clinical triad of parkinsonism, cerebellar imbalance, and severe orthostatic hypotension—often accompanied by slow eye movements—provides a roadmap for diagnosis. The potential interplay between synuclein and tau opens new avenues for biomarker development and therapeutic intervention. Research efforts are now focused on developing drugs that can prevent synuclein aggregation, enhance its clearance, or block the propagation of pathological conformers between cells.